Introduction to Osteoporosis

  • Claus Christiansen
Part of the Medical Science Symposia Series book series (MSSS, volume 13)


Osteoporosis is a major and growing health problem worldwide. It affects an estimated 75 million people in the United States, Europe, and Japan combined, including one in three postmenopausal women and a majority of the elderly, including a substantial number of men.


Bone Mineral Density Postmenopausal Woman Bone Loss Bone Mass Vertebral Fracture 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    World Health Organization. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO Technical Report Series 843. Geneva: WHO, 1994.Google Scholar
  2. 2.
    Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ 1996;312:1254–59.PubMedGoogle Scholar
  3. 3.
    Riggs BL, Mann KG. Assessment of bone turnover in osteoporosis using biochemical marker. In: Christiansen C, et al, editors. Osteoporosis, vol 2. Copenhagen: Osteopress ApS, 1987:672–76.Google Scholar
  4. 4.
    Christiansen C, Roedbro P, Tjellesen L. Serum alkaline phosphatase during hormone treatment in early postmenopausal women. Acta Med Scand 1984;216:11–17.PubMedCrossRefGoogle Scholar
  5. 5.
    Horsman A, Jones M, Francis R, Nordin BBC. The effect of estrogen dose on postmenopausal bone loss. N Engl J Med 1983;309:1405–7.PubMedCrossRefGoogle Scholar
  6. 6.
    Christensen MS, Hagen C, Christiansen C, Transbol I. Dose response evaluation of cyclic estrogen/gestagen in postmenopausal women. Placebo-controlled trial of its gynecologic and metabolic actions. Am J Obstet Gynecol 1982;144:873–79.PubMedGoogle Scholar
  7. 7.
    Lindsay R, Hart CM, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1983;63:759–63.Google Scholar
  8. 8.
    Alexandersen P, Hassager C, Sandholdt I, Riis BJ, Christiansen C. The effect of cyclophasic hormone therapy on postmenopausal bone mass and bone turnover. J Bone Min Res 1997;12(Suppl.1):S499Google Scholar
  9. 9.
    Bjarnason NH, Hassager C, Christiansen C. 17β oestradiol 1 mg and 2 mg in combinations with a new gestagen, Gestodene are equally preventive on bone loss in early postmenopausal women. Bone 1997;20, 93S.CrossRefGoogle Scholar
  10. 10.
    Bjarnason NH, Hassager C, Christiansen C. Profile of a new substitution principle: Low dose 17β estradiol and gestodene. Acta Obstet Gynecol Scand 1997;76(Suppl.167):S56.Google Scholar
  11. 11.
    Bjarnason NH, Bjarnason K, Haarbo J, Rosenquist C, Christiansen C. Tibolone: Prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 1996;81:2419–22.PubMedCrossRefGoogle Scholar
  12. 12.
    Stadberg E, Mattson L-C, Uvebrant M. Low doses 17-beta-estradiol and norethisterone acetate as continuous combined hormone replacement therapy in postmenopausal women: Lipid metabolic effects. Menopause 1996;3:90–96.Google Scholar
  13. 13.
    Christiansen C, Nilas L, Riis BJ, Radbro P, Deftos L. Uncoupling of bone formation and resorption by combined oestrogen and progestogen therapy in postmenopausal osteoporosis. Lancet 1985, ii:800–801.CrossRefGoogle Scholar
  14. 14.
    Ribot C, Tremollieraaes F, Pouillaaes JM. Cyclic Estraderm TTS 50 plus oral progestogen in the prevention of postmenopausal bone loss over 24 months. In: Christiansen C, Overgaard K, editors. Osteoporosis. Vol 2. Copenhagen: Osteopress ApS, 1990:1979–84.Google Scholar
  15. 15.
    Lindsay R, Hart DM, Maclean A, Clark AC, Kraszewski A, Garnwood J. Bone response to termination of estrogen treatment. Lancet 1978;1:1321–27.Google Scholar
  16. 16.
    Christiansen C, Christensen MS, Transbøl I. Bone mass in postmenopausal women after withdrawal of estrogen/gestagen replacement therapy. Lancet 1981;1:459–61.PubMedCrossRefGoogle Scholar
  17. 17.
    Weiss NS, Ure CL, Ballard JH, Williams AR, Dalin JR. Decreased risk of fractures of the hip and lower forearm with postmenopausal use of estrogen. N Engl J Med 1980;303:1195–98.PubMedCrossRefGoogle Scholar
  18. 18.
    Kiel DP, Felson DT, Andersen JJ, Wilson PWF, Moskowitz MA. Hip fracture and the use of estrogens in postmenopausal women. The Framingham study. N Engl J Med 1987;317:1169–74.PubMedCrossRefGoogle Scholar
  19. 19.
    Jordan VC. Third annual William L. McGuire memorial lecture. “Studies on the estrogen receptor in breast cancer” — 20 years as a target for the treatment and prevention of cancer. Breast Cancer Res Treat 1995;36:367–85.CrossRefGoogle Scholar
  20. 20.
    Delmas PD, Bjarnason NH, Mitlak BH, et al. The effects of raloxifene on bone mineral density, serum cholesterol, and uterine endometrium in postmenopausal women. N Engl J Med 1997;337:1641–47.PubMedCrossRefGoogle Scholar
  21. 21.
    Lufkin EG, Whitaker R, Argueta R, Caplan RH, Nickelsen T, Riggs BL. Raloxifene treatment of postmenopausal osteoporosis. J Bone Miner Res 1997; 12(Suppi. 1):S150.Google Scholar
  22. 22.
    Bjarnason NH, Haarbo J, Byrjalsen I, Kauffman RF, Christiansen C. Raloxifene inhibits aortic accumulation of cholesterol in ovariectomized, cholesterol-fed rabbits. Circulation 1997;96: 1964–69.PubMedGoogle Scholar
  23. 23.
    Bjarnason K, Skrumsager BK, Kiehr B. Levomeloxifene, a new partial estrogen receptor agonist, demonstrates anti-resorptive and anti-atherogenic properties in postmenopausal women. J Bone Miner Res 1997;12(Suppl.l):S346.Google Scholar
  24. 24.
    Ke HZ, Chidsey-Frink KL, Oi H, et al. Droloxifene increases bone mass in ovariectomized rats with established osteopenia. J Bone Miner Res 1997;12(Suppl.l):S349.Google Scholar
  25. 25.
    Hosking D, Chilvers CED, Christiansen C, et al. Prevention of bone loss with alendronate in postmenopausal women under age 60 years of age. N Engl J Med 1998;338:485–92.PubMedCrossRefGoogle Scholar
  26. 26.
    Weiss S, McClung M, Gilschrist N, et al. Five-years efficacy and safety of oral alendronate for prevention of osteoporosis in early postmenopausal women. J Bone Miner Res 1997;12(Suppl.l):S144.Google Scholar
  27. 27.
    Ravn P, Clemmesen B, Riis BJ, Christiansen The effect on bone mass and bone markers of different doses of ibandronate: A new bisphosphonate for prevention and treatment of osteoporosis: a 1-year, randomized, double-blind, placebo-controlled dose-finding study. Bone 1996;5:527–33.CrossRefGoogle Scholar
  28. 28.
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracture. Fracture intervention trial research group. Lancet 1996;348:1535–41.PubMedCrossRefGoogle Scholar
  29. 29.
    Cummings SR, Black DM, Thompson DE for the FIT research group. Alendronate reduces the risk of vertebral fractures in women without pre-existing vertebral fractures: Results of the fracture intervention trial. J Bone Miner Res 1997;12(Suppl.l):S149.Google Scholar
  30. 30.
    Storm TM, Thamsborg G, Steiniche T, Genant HK, Storensen OM. Effect of intermittent cyclical etidronate therapy on bone mass and fracture rate in women with postmenopausal osteoporosis. N Engl J Med 1990;322:1265–71.PubMedCrossRefGoogle Scholar
  31. 31.
    Nelson BW, Harris ST, Genant HK, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med 1990;323:73–79.CrossRefGoogle Scholar

Copyright information

© Kluwer Academic Publishers and Fondazione Giovanni Lorenzini 1999

Authors and Affiliations

  • Claus Christiansen

There are no affiliations available

Personalised recommendations